Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001104659-25-102591·D. E. SHAW & CO, L.P.
Schedule 13G ownership disclosure
Keros Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 492327101
Event date: 2025-10-20
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- D. E. Shaw & Co., L.P.
Shares: 1,545,948.00 · Class: 5.1%
- D. E. Shaw & Co., L.L.C.
Shares: 1,537,348.00 · Class: 5.0%
- David E. Shaw
Shares: 1,545,948.00 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-102591
- Form type
- SCHEDULE 13G
- Filer
- D. E. SHAW & CO, L.P.
- CIK
- CIK 1009268
- Filed
- Oct 27, 2025
- Reporting period
- Oct 20, 2025
- Description
- Schedule 13G beneficial ownership